01—Abstract
Summary
Summary of the 8-K filed February 12, 2024. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported fourth-quarter and full-year 2023 results in a press release dated February 12, 2024, furnished as Exhibit 99.1 to this Form 8-K under Item 2.02.
For the fourth quarter, revenue increased 26.5% to $498.4 milliona, net new business awards were $614.7 million (a 1.23x net book-to-bill ratio), and GAAP net income was $78.3 million, or $2.46 per diluted share. EBITDA rose 19.2% to $95.8 million. For the full year 2023, revenue increased 29.2% to $1,885.8 million, GAAP net income was $282.8 million, or $8.88 per diluted share, and EBITDA was $362.5 million.
Backlog as of December 31, 2023 increased 20.2% to $2,813.0 millionb. The company issued 2024 guidance calling for revenue of $2.150 billion to $2.200 billion, representing growth of 14.0% to 16.7% over 2023 revenue. It expects GAAP net income of $326.0 million to $348.0 million, diluted EPS of $10.18 to $10.87, and EBITDA of $400.0 million to $430.0 million.
The guidance assumes a tax rate of 16.0% to 17.0%, interest income of $18.4 millionc, and 32.0 million diluted shares, and excludes any future share repurchases. On the balance sheet, cash and cash equivalents were $245.4 million at December 31, 2023, up from $28.3 million a year earlier, and operating cash flow for the full year was $433.4 million. The company repurchased 781,068 shares for $144.0 million in 2023 and had $308.8 million remaining under its repurchase program.
The filing also notes a conference call on February 13, 2024 at 9:00 a.m. ET.
02—Key points
Key Highlights
- Q4 2023 revenue of $498.4 million, up 26.5% from $394.1 million; constant-currency growth of 26.0%
- Q4 2023 net new business awards of $614.7 million, up 26.7%, yielding a net book-to-bill ratio of 1.23x
- Full-year 2023 revenue of $1,885.8 million, up 29.2%, with GAAP diluted EPS of $8.88 versus $7.28 in 2022
- Backlog at December 31, 2023 of $2,813.0 million, up 20.2% year over year
- 2024 guidance: revenue of $2.150–$2.200 billion, GAAP net income of $326.0–$348.0 million, and diluted EPS of $10.18–$10.87
- 2024 EBITDA guidance of $400.0–$430.0 million, with a full-year EBITDA margin of 19.2% reported for 2023
- Cash of $245.4 million at year-end 2023; $144.0 million of share repurchases in 2023 with $308.8 million remaining authorization
03—Questions
Frequently Asked Questions
How did Medpace perform in the fourth quarter of 2023?
Revenue rose 26.5% to $498.4 million and GAAP net income was $78.3 million, or $2.46 per diluted share, compared with $68.7 million, or $2.12 per diluted share, a year earlier. EBITDA increased 19.2% to $95.8 million.
What does the 2024 guidance imply for the company?
Medpace forecasts 2024 revenue of $2.150 billion to $2.200 billion, which the filing states represents growth of 14.0% to 16.7% over 2023. It expects GAAP net income of $326.0 million to $348.0 million and diluted EPS of $10.18 to $10.87.
What were the key new business and backlog metrics?
Q4 2023 net new business awards were $614.7 million, for a net book-to-bill ratio of 1.23x. Full-year awards were $2,356.7 million, a 1.25x book-to-bill ratio, and backlog at December 31, 2023 reached $2,813.0 million, up 20.2%.
How much capital did the company return to shareholders in 2023?
Medpace repurchased 781,068 shares for $144.0 million during 2023, with no repurchases in the fourth quarter. As of December 31, 2023, $308.8 million remained under its authorized repurchase program.
What is the status of the company's liquidity?
Cash and cash equivalents were $245.4 million at December 31, 2023, compared with $28.3 million at the end of 2022. Net cash provided by operating activities for the full year 2023 was $433.4 million.
04—Continue